Depotech(depo) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo)

DEPO 7.300

+1.7%

Aug 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: StockDoc who wrote (812)	5/26/1998 8:12:00 PM
From: John McCarthy	Read Replies (1) of 887

stockdoc - <<The guy who heads the division and that handles the "case" at the FDA (Temple) is famous for his consistent, impartial and scientific approach to NDAs. >> Give me a break. The FDA absolutely screwed over NPRO with respect to Paxene. Nothing impartial about it. BMS filed for Orphan Drug status for K.S. on Phase 2 crap and the FDA rammed it thru. In fact, its not REALLY clear who filed for BMS - them or the FDA. Why? To protect the goddam clinicals going on around the world on Taxol. i.e. doctor money And who gets the brunt of it - not the just the investors - how about the 200,000 women who had an OPTION taken away from them - simply because of GREED. And then you pontificate like you really have a clue. And now - BTW - the FDA (via Merck) is pulling the same crap with respect to a cholesterol drug. I strongly disagree with your statement. Regards, John McCarthy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next